Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?

Therapeutic Drug Monitoring

Volumn 20, Issue 6, 1998, Pages 717-721

  Mahmood, Iftekhar ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Woodmont Office Center II   (United States)

Author keywords

MAO B inhibition; Reduction in dose; Selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; SELEGILINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

BLOOD PLATELETS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEVODOPA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SELEGILINE;

EID: 0031785758     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199812000-00024     Document Type: Article

References (12)

1. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991;3:228-48.
2. Fowler JS, MacGregor RR, Wolf AP. Mapping hyman brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 1987;235:481-5.
3. Yoshida T, Yamada Y, Yamamoto T, et al. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rats: Relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986;16:129-39.
4. Heinonen EH, Anttila MI, Karnani HL, et al. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 1997;37:602-9.
5. Mahmood I, Neau SH, Mason WD. An enzymatic assay for the analysis of selegiline in plasma. J Pharm Biomed Anal 1994;12: 895-9.
6. Knoll J. Deprenyl facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm 1987;25:45-66.
7. Heinonen E, Antilla M, Lammintausta R. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolism. Clin Pharmacol Ther 1994;56:742-9.
8. Parada MD, Cesura AM, Launay JM, et al. Platelets as a model for neurons. Experientia 1988;44:115-26.
9. Heinonen EH, Anttila MI, Karnani HL, et al. Inhibition of platelet monoamine oxidase type B by selegiline. J Clin Pharmacol 1997; 37:597-601.
10. Andreu N, Damase-Michel C, Senard JM, et al. A dose-ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity. Mov Disord 1997;12:293-6.
11. Mahmood I, Marinac JS, Willsie S, et al. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm Drug Disp 1995;16:535-45.
12. Barret JS, Rohatagi S, Dewwitt KE, et al. The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug eldepryl (selegiline hydrochloride). Am J Ther 1996;3:298-313.